Novavax is undervalued, presenting an attractive risk-reward profile for long-term investors. Click here to find out why NVAX ...

Novavax (NVAX) smashed its Q1 2025 earnings today. The stock rocketed 33% in pre-market trading after the company reported a stunning $518 million profit for Q1 2025. This marks a complete turnaround ...

Novavax Inc. (NASDAQ:NVAX) reported first-quarter 2025 sales of $667 million, compared to $94 million a year ago, beating the ...

Vaccine maker Novavax stock jumped double digits on Thursday after the company reported its quarterly sales had more than ...

After more than a month of speculation over how the FDA will rule on Novavax’s application for an updated formulation of its ...

Novavax (NASDAQ:NVAX) shares climbed ~35% in the premarket on Thursday after the COVID-19 vaccine maker lifted its full-year ...

Novavax, Inc. (NVAX) said it has updated the terms of the collaboration and licensing agreement with Takeda. The company noted that the improved financial terms of the amended ...

Novavax (NASDAQ:NVAX) has updated the terms of the previously announced collaboration and licensing agreement with Takeda (TAK).

Improved financial terms for Novavax and streamlined operations will help both companies better meet the needs of the Japanese market Nuvaxovid®, a protein-based ...

The new policy, revealed by the Department of Health and Human Services on Wednesday, would make vaccines “less available and ...